Rectal cancer and synchronous metastases: Resection of primary tumor or not?

Autor: H.J. Schmoll, T. Trarbach

Publikováno v: Gastroentérologie Clinique et Biologique. 33:1098-1100

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1811b77cf27f5033753cec24f8761b13
https://doi.org/10.1016/j.gcb.2009.10.011

Leberchirurgie

Autor: K.J. Paquet, H.U. Baer, M.W. Büchler, F. Holzinger, W.D. Heine, E. Klar, F. Mühlbacher, H. Schild, H.J. Schmoll

Publikováno v: Visceral Medicine. 14:243-247

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9a8375b5bd9932f83c3af176a8d4a462
https://doi.org/10.1159/000012500

Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease

Autor: V. Diehl, M. Loeffler, M. Pfreundschuh, U. Ruehl, D. Hasenclever, H. Nisters-Backes, M. Sieber, K. Smith, H. Tesch, W. Geilen, M. Adler, H. Bartels, U. Brandenburg, P. Diezler, G. Doelken, J. Enzian, R. Fuchs, W. Gassmann, H. Gerhartz, U. Hagenaukamp, T. Hecht, E. Hiller, H. Hinkelbein, B. Lathan, H. Kirchner, G. Kuehn, H. Kuerten, U. Loos, B. Makoski, W. Oertel, S. Petsch, R. Pfab, H. Pflueger, M. Planker, R. Rohioff, H. Sack, S. Samandari, R. Sauer, K. Schalk, G. Schmitz, W. Schoppe, G. Schwieder, S. Szepesi, J. Teichmann, W. Wilhelmy, P. Worst, R. Fischer, A. Georgii, K. Huebner, E.W. Schwarze, R. Rohloff, U. Hagen-Aukamp, H. Kürten, M. Westerhausen, H. Pflüger, J. Entzian, G. Dölken, H. Ernst, J. König, H. Hellriegel, G. Kühn, U. Rühl, null Szepesi, U. Schulz, S. Theml, R. Staiger, W. Haase, T. Wagner, null Brandenburg, I. Boldt, H.J. Schmoll, H. Emminger, W. Gaβmann, T. Brix, B. Mödder, H. Hennekeuser, G. Schlimok, null Doukas, A.-C. Voss, B. Krüger, K. Kutzner, F. Hinrichs, A. Temmesfeld, T. Luska, H.D. Schick, J. Preiβ, W. Gärtner, W. Mende, W. Alberti, U. Hoffmann, D. Urbanitz, null Heide, H. Siebner, K.H. van de Weyer, D. Dornoff, E. Renner, M. Cohen, P. Czygan, H.W. Scheja, J. Schoenemann, M. Rochell, U. Peters, K. Koniczek, D. Mitrenga, U. Cammerer, W. Mantel, K. Hübner, Volker Diehl

Publikováno v: Annals of Oncology. 6:901-910

Summary Objective It was the aim of this prospective randomized multicenter study to compare chemotherapy and radiotherapy as consolidation treatments in patients achieving complete remission (CR) after 6 cycles of doxorubicin-containing chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3495bc77f188e9ed1f1382f6cc7d12b1
https://doi.org/10.1093/oxfordjournals.annonc.a059357

Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck

Autor: G. Catimel, J. Verweij, V. Mattijssen, A. Hanauske, M. Piccart, J. Wanders, H. Franklin, N. Le Bail, M. Clavel, S.B. Kaye, T. Cerny, H.H. Hansen, S. Kaplan, M. Marty, N. Pavlidis, H.J. Schmoll, C. Sessa, P. Siegenthaler, W. Ten Bokkel Huinink, A.T. Van Oosterom, J.B. Vermorken

Publikováno v: Annals of Oncology. 5:533-537

Summary Background Docetaxel (Taxotere®) is a new cytotoxic agent acting as a promotor of tubulin polymerisation with broad spectrum antitumor activity in preclinical testing. Phase I clinical trials have shown promising activity of docetaxel in pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::594522c3a18f938a3d9d1bbb677d7758
https://doi.org/10.1093/oxfordjournals.annonc.a058908

Preoperative Chemoradiotherapy and Postoperative Chemotherapy with Capecitabine +/- Oxaliplatin in Locally Advanced Rectal Cancer: Interim Analysis for Disease-Free Survival of Petacc 6

Autor: Murielle Mauer, R.D. Hofheinz, F. Fauth, H.J. Schmoll, Carlo Messina, J.F. Daisne, Manfred P. Lutz, Timothy J. Price, P. Schmidt, S. Hollerbach, Carla Hannig, Bernard Nordlinger, Niall C. Tebbutt, John Zalcberg, Jos Janssens, Karin Haustermans, H. Reinel, Baruch Brenner, E. Van Cutsem, K. Caca

Publikováno v: Annals of Oncology. 25:iv170

Aim: The PETACC-6 trial investigates the role of oxaliplatin in addition to preoperative chemoradiation (CRT) and adjuvant chemotherapy (CT) with capecitabine to improve disease-free survival (DFS) in locally advanced rectal cancer. Methods: Patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d87c1ac721adf17c23c79c68bd784b64
https://doi.org/10.1093/annonc/mdu333.8